Robert W. Simms, MD
Boston University School of Medicine
Dept of Medicine
Rheumatology (Arthritis) Section

MD, University of Rochester School of Medicine and Dentistry

Expertise in scleroderma translational research and clinical trials.

Section Chief of Rheumatology
Boston University School of Medicine
Rheumatology (Arthritis) Section

United States Pulmonary Hypertension Scientific Registry
10/11/2016 - 12/31/2019 (PI)
United States Pulmonary Hypertension Sci

A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with 'Systemic Sclerosis associated Interstitial Lung
08/22/2016 - 08/21/2019 (PI)
Boehringer Ingelheim Pharmaceuticals

Autologous Adipose-Derived Regenerative Cells
12/09/2015 - 06/01/2019 (PI)
Cytori Therapeutics, Inc.

Efficacy and safety of SAR156597 in the treatment of diffuse cutaneous Systemic Sclerosis (dcSSc): A randomized, double-blind, placebo-controlled, 24-week, proof of concept study
04/18/2017 - 04/17/2019 (PI)
Sanofi-Aventis, U.S., LLC

A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Diffuse Cutaneous Systemic Sclerosis
12/01/2015 - 11/30/2018 (PI)
Corbus Pharmaceuticals Holdings, Inc.

A Phase II, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of abituzumab in subjects with systemic sclerosis-associated interstitia
08/05/2016 - 04/30/2018 (PI)
EMD Serono Research & Development Instit

Rituximab for Treatment of SSc-PAH (ASC01)
05/01/2016 - 04/30/2018 (PI)
University of California, San Francisco NIH NIAID

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Tocilizumab versus Placebo in Patients with Systemic Sclerosis
04/05/2016 - 04/04/2018 (PI)
Genentech, Inc.

A Phase II Multi-Center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation with Post Transplant Maintenance for the Treatment of
01/06/2016 - 01/05/2018 (PI)
Fred Hutchinson Cancer Research Center Scleroderma Res Fdn

ASSET: A Phase II study to evaluate subcutaneous abatacept vs. placebo in diffuse cutaneous systemic sclerosis - a double-blind, placebo-controlled, randomized controlled trial [IMI101-344]
03/31/2015 - 11/30/2017 (Co-PI)
PI: Robert A. Lafyatis, MD
Regents of the Univ. of Michigan Bristol-Myers Squibb

Showing 10 of 39 results. Show All Results

Yr Title Project-Sub Proj Pubs
2015 Core B Clinical Core 5P50AR060780-05-7136 25
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Toyama T, Looney AP, Baker BM, Stawski L, Haines P, Simms R, Szymaniak AD, Varelas X, Trojanowska M. Therapeutic targeting of TAZ and YAP by dimethyl fumarate in systemic sclerosis fibrosis. J Invest Dermatol. 2017 Sep 01.View Related Profiles. PMID: 28870693.
  2. Lafyatis R, Mantero JC, Gordon J, Kishore N, Carns M, Dittrich H, Spiera R, Simms RW, Varga J. Inhibition of beta-catenin signaling in the skin rescues cutaneous adipogenesis in systemic sclerosis: a randomized, double blind, placebo-controlled trial of C-82. J Invest Dermatol. 2017 Aug 11.View Related Profiles. PMID: 28807667.
  3. Makino K, Makino T, Stawski L, Mantero JC, Lafyatis R, Simms R, Trojanowska M. Blockade of PDGF Receptors by Crenolanib Has Therapeutic Effect in Patient Fibroblasts and in Preclinical Models of Systemic Sclerosis. J Invest Dermatol. 2017 Aug; 137(8):1671-1681.View Related Profiles. PMID: 28433542.
  4. Man A, Correa JK, Ziemek J, Simms RW, Felson DT, Lafyatis R. Development and validation of a patient-reported outcome instrument for skin involvement in patients with systemic sclerosis. Ann Rheum Dis. 2017 Aug; 76(8):1374-1380.View Related Profiles. PMID: 28213563; DOI: 10.1136/annrheumdis-2016-210534;.
  5. Chung L, Fairchild RM, Furst DE, Li S, Alkassab F, Bolster MB, Csuka ME, Derk CT, Domsic RT, Fischer A, Frech T, Gomberg-Maitland M, Gordon JK, Hinchcliff M, Hsu V, Hummers LK, Khanna D, Medsger TA, Molitor JA, Preston IR, Schiopu E, Shapiro L, Hant F, Silver R, Simms R, Varga J, Steen VD, Zamanian RT. Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry. Clin Exp Rheumatol. 2016 Nov 10. PMID: 27908301.
  6. Rice LM, Mantero JC, Stifano G, Ziemek J, Simms RW, Gordon J, Domsic R, Lafyatis R. A Proteome-Derived Longitudinal Pharmacodynamic Biomarker for Diffuse Systemic Sclerosis Skin. J Invest Dermatol. 2017 Jan; 137(1):62-70.View Related Profiles. PMID: 27640094; DOI: 10.1016/j.jid.2016.08.027;.
  7. Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, Silver R, Steen V, Strange C, Wise R, Wigley F, Mayes M, Riley DJ, Hussain S, Assassi S, Hsu VM, Patel B, Phillips K, Martinez F, Golden J, Connolly MK, Varga J, Dematte J, Hinchcliff ME, Fischer A, Swigris J, Meehan R, Theodore A, Simms R, Volkov S, Schraufnagel DE, Scholand MB, Frech T, Molitor JA, Highland K, Read CA, Fritzler MJ, Kim GHJ, Tseng CH, Elashoff RM. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016 Sep; 4(9):708-719.View Related Profiles. PMID: 27469583; PMCID: PMC5014629; DOI: 10.1016/S2213-2600(16)30152-7;.
  8. Christmann RB, Wooten A, Sampaio-Barros P, Borges CL, Carvalho CR, Kairalla RA, Feghali-Bostwick C, Ziemek J, Mei Y, Goummih S, Tan J, Alvarez D, Kass DJ, Rojas M, de Mattos TL, Parra E, Stifano G, Capelozzi VL, Simms RW, Lafyatis R. miR-155 in the progression of lung fibrosis in systemic sclerosis. Arthritis Res Ther. 2016 Jul 05; 18(1):155.View Related Profiles. PMID: 27377409; PMCID: PMC4932708; DOI: 10.1186/s13075-016-1054-6;.
  9. Ziemek J, Man A, Hinchcliff M, Varga J, Simms RW, Lafyatis R. The relationship between skin symptoms and the scleroderma modification of the health assessment questionnaire, the modified Rodnan skin score, and skin pathology in patients with systemic sclerosis. Rheumatology (Oxford). 2016 May; 55(5):911-7.View Related Profiles. PMID: 26880832; DOI: 10.1093/rheumatology/kew003;.
  10. Khanna D, Berrocal VJ, Giannini EH, Seibold JR, Merkel PA, Mayes MD, Baron M, Clements PJ, Steen V, Assassi S, Schiopu E, Phillips K, Simms RW, Allanore Y, Denton CP, Distler O, Johnson SR, Matucci-Cerinic M, Pope JE, Proudman SM, Siegel J, Wong WK, Wells AU, Furst DE. The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. Arthritis Care Res (Hoboken). 2016 Feb; 68(2):167-78. PMID: 26806474; PMCID: PMC4818571; DOI: 10.1002/acr.22804;.
Showing 10 of 81 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 81 publications over 27 distinct years, with a maximum of 8 publications in 1996 and 2014 and 2016

In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Contact for Mentoring:

75 E. Newton St Evans Building
Boston MA 02118
Google Map

Simms's Networks
Click the "See All" links for more information and interactive visualizations
Similar People
Same Department